Stratified analyses based on various factors such as age, HER2 status, ER, postoperative stage, lymph node metastasis, and risk classification also showed no difference in DFS between the two groups. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.